Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: Review and future prospects

Immunotherapy

Volumn 6, Issue 6, 2014, Pages 725-736

  He, Yukai ^a   Hong, Yuan ^a   Mizejewski, Gerald J ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b WADSWORTH CENTER   (United States)

Author keywords

antigen engineering; cancer vaccine; epitope optimization; genetic immunization; hepatocellular carcinoma; immunotherapy; recombinant lentivector

Indexed keywords

ALPHA FETOPROTEIN; CANCER VACCINE; DENDRITIC CELL VACCINE; GPC3 PROTEIN; ONCOFETAL ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; EPITOPE;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CYTOKINE INDUCED KILLER CELL; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; CARCINOMA, HEPATOCELLULAR; FORECASTING; GENETICS; IMMUNOLOGY; LIVER NEOPLASMS; PROCEDURES; PROTEIN ENGINEERING; TRENDS; VACCINATION;

ALPHA-FETOPROTEINS; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; FORECASTING; HUMANS; LIVER NEOPLASMS; PROTEIN ENGINEERING; VACCINATION;

EID: 84904621154     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.46     Document Type: Review

References (83)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893-2917 (2010).
2. CDC. United States Cancer Statistics Public Information Data. http://wonder.cdc.gov/cancer.html
3. Chang MH, You SL, Chen CJ et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl Cancer Inst. 101(19), 1348-1355 (2009).
4. Wright TL. Introduction to chronic hepatitis B infection. Am. J. Gastroenterol. 101(Suppl. 1), S1-S6 (2006).
5. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int. J. Med. Sci. 3(2), 41-46 (2006).
6. Welzel TM, Graubard BI, Quraishi S et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am. J. Gastroenterol. 108(8), 1314-1321 (2013).
7. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126(2), 460-468 (2004).
8. Corey KE, Pratt DS. Current status of therapy for hepatocellular carcinoma. Ther. Adv. Gastroenterol. 2(1), 45-57 (2009).
9. Kao WY, Su CW, Chau GY, Lui WY, Wu CW, Wu JC. A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery. World J. Surg. 35(4), 858-867 (2011).
10. Pardee AD, Butterfeld LH. Immunotherapy of hepatocellular carcinoma: unique challenges and clinical opportunities. Oncoimmunology 1(1), 48-55 (2012).
11. Bei R, Mizejewski GJ. Alpha fetoprotein is more than a hepatocellular cancer biomarker: from spontaneous immune response in cancer patients to the development of an AFP-based cancer vaccine. Curr. Mol. Med. 11(7), 564-581 (2011).
12. Buonaguro L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM. Challenges in cancer vaccine development for hepatocellular carcinoma. J. Hepatol. 59(4), 897-903 (2013).
13. Zhu AX, Gold PJ, El-Khoueiry AB et al. First-in-man Phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 19(4), 920-928 (2013).
14. Mizejewski GJ. Alpha-fetoprotein (AFP)-derived peptides as epitopes for hepatoma immunotherapy: a commentary. Cancer Immunol. Immunother. 58(2), 159-170 (2009).
15. Feng M, Ho M. Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett 588(2), 377-382 (2013).
16. Jiang J, Wu C, Lu B. Cytokine-induced killer cells promote antitumor immunity. J. Transl. Med. 11, 83 (2013).
17. Mesiano G, Todorovic M, Gammaitoni L et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin. Biol. Ther. 12(6), 673-684 (2012).
18. Takayama T, Sekine T, Makuuchi M et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356(9232), 802-807 (2000).
19. Hui D, Qiang L, Jian W, Ti Z, Da-Lu K. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig. Liver Dis. 41(1), 36-41 (2009).
20. Xie F, Zhang X, Li H et al. Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. PLoS ONE7(8), e42879 (2012).
21. Zhong JH, Ma L, Wu LC et al. Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. Int. J. Clin. Pract. 66(1), 21-27 (2012).
22. Pan K, Li YQ, Wang W et al. The effcacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann. Surg. Oncol. 20(13), 4305-4311 (2013).
23. Huang ZM, Li W, Li S et al. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J. Immunother. 36(5), 287-293 (2013).
24. Gonzalez-Carmona MA, Marten A, Hoffmann P et al. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specifc and strong immune response against hepatocellular carcinoma cells. Liver Int. 26(3), 369-379 (2006).
25. Lee WC, Wang HC, Jeng LB et al. Effective treatment of small murine hepatocellular carcinoma by dendritic cells. Hepatology 34(5), 896-905 (2001).
26. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J. Immunother. 28(5), 496-504 (2005).
27. Palmer DH, Midgley RS, Mirza N et al. A Phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 49(1), 124-132 (2009).
28. Chen M, Li G, Yan J et al. Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma. Clin. Chim. Acta 423, 105-111 (2013).
29. Tada F, Abe M, Hirooka M et al. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int. J. Oncol. 41(5), 1601-1609 (2012).
30. Flecken T, Schmidt N, Hild S et al. Immunodominance and functional alterations of tumor-associated antigen-specifc CD8 T-cell responses in hepatocellular carcinoma. Hepato logy 59(4), 1415-1426 (2013).
31. Greten TF, Forner A, Korangy F et al. A Phase II open label trial evaluating safety and effcacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 10, 209 (2010).
32. Butterfeld LH, Ribas A, Dissette VB et al. A Phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin. Cancer Res. 12(9), 2817-2825 (2006).
33. Liu C, Xiao GQ, Yan LN et al. Value of alpha-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J. Gastroenterol. 19(11), 1811-1819 (2013).
34. Grimm CF, Ortmann D, Mohr L et al. Mouse alpha-fetoprotein-specifc DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology 119(4), 1104-1112 (2000).
35. Vollmer CM Jr, Eilber FC, Butterfeld LH et al. Alpha-fetoprotein-specifc genetic immunotherapy for hepatocellular carcinoma. Cancer Res. 59(13), 3064-3067 (1999).
36. Butterfeld LH, Ribas A, Meng WS et al. T-cell responses to HLA-A•0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin. Cancer Res. 9(16 Pt 1), 5902-5908 (2003).
37. Tian G, Yi JL, Xiong P. Specifc cellular immunity and antitumor responses in C57BL/6 mice induced by DNA vaccine encoding murine AFP. Hepatobiliary Pancreat. Dis. Int. 3(3), 440-443 (2004).
38. Cany J, Barteau B, Tran L et al. AFP-specifc immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice. J. Hepatol. 54(1), 115-121 (2011).
39. Hanke P, Serwe M, Dombrowski F, Sauerbruch T, Caselmann WH. DNA vaccination with AFP-encoding plasmid DNA prevents growth of subcutaneous AFP-expressing tumors and does not interfere with liver regeneration in mice. Cancer Gene Ther. 9(4), 346-355 (2002).
40. Tan XH, Zhu Q, Liu C, Liu XL, Shao X T, Wei B. Immunization with dendritic cells infected with human AFP adenovirus vector effectively elicits immunity against mouse hepatocellular carcinomas. Zhonghua Zhong Liu Za Zhi 28(1), 13-16 (2006).
41. Pang XH, Chen MS, Jia WH, Zhou XX. Inhibitory effects of human AFP-derived peptide-pulsed dendritic cells on mouse hepatocellular carcinoma. Ai Zheng 27(12), 1233-1238 (2008).
42. Zhang W, Liu J, Wu Y et al. Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous alpha fetoprotein in mice. Biochem. Biophys. Res. Commun. 376(1), 10-14 (2008).
43. Lan YH, Li YG, Liang ZW et al. A DNA vaccine against chimeric AFP enhanced by HSP70 suppresses growth of hepatocellular carcinoma. Cancer Immunol. Immunother. 56(7), 1009-1016 (2007).
44. Wang X, Lin H, Wang Q. Specifc genetic immunotherapy induced by recombinant vaccine alpha-fetoprotein-heat shock protein 70 complex. Phys. Proc. 33, 738-742 (2012).
45. Rodriguez MM, Ryu SM, Qian C et al. Immunotherapy of murine hepatocellular carcinoma by alpha-fetoprotein DNA vaccination combined with adenovirus-mediated chemokine and cytokine expression. Hum. Gene Ther. 19(7), 753-759 (2008).
46. Meng WS, Butterfeld LH, Ribas A et al. Alpha-fetoprotein-specifc tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res. 61(24), 8782-8786 (2001).
47. Saeki A, Nakao K, Nagayama Y et al. Diverse effcacy of vaccination therapy using the alpha-fetoprotein gene against mouse hepatocellular carcinoma. Int. J. Mol. Med. 13(1), 111-116 (2004).
48. Evdokimova VN, Butterfeld LH. Alpha-fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer. Expert Opin. Biol. Ther. 8(3), 325-336 (2008).
49. Butterfeld LH, Koh A, Meng W et al. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res. 59(13), 3134-3142 (1999).
50. Butterfeld LH, Meng WS, Koh A et al. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J. Immunol. 166(8), 5300-5308 (2001).
51. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological signifcance and temporospatial distribution. Cancer Res. 57(22), 5179-5184 (1997).
52. Iwama T, Horie K, Yoshikawa T et al. Identifcation of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide. Int. J. Oncol. 42(3), 831-838 (2013).
53. Nakatsura T, Komori H, Kubo T et al. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin. Cancer Res. 10(24), 8630-8640 (2004).
54. Komori H, Nakatsura T, Senju S et al. Identifcation of HLA-A2-or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specifc immunotherapy of hepatocellular carcinoma. Clin. Cancer Res. 12(9), 2689-2697 (2006).
55. Sawada Y, Yoshikawa T, Nobuoka D et al. Phase I trial of a glypican-3-de rived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin. Cancer Res. 18(13), 3686-3696 (2012).
56. Guevara-Patino JA, Engelhorn ME, Turk MJ et al. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J. Clin. Invest. 116(5), 1382-1390 (2006).
57. Liu Y, Peng Y, Mi M et al. Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice. J. Immunol. 182(10), 5960-5969 (2009).
58. Overwijk WW, Tsung A, Irvine KR et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of 'self-reactive, tumoricidal T cells using high-affnity, altered peptide ligand. J. Exp. Med. 188(2), 277-286 (1998).
59. Tran L, Judor JP, Gauttier V et al. The immunogenicity of the tumor-associated antigen alp h a-fe to protein is enhanced by a fusion with a transmembrane domain. J. Biomed. Biotechnol. 878657 (2012) (2012).
60. Dyall R, Bowne WB, Weber LW et al. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188(9), 1553-1561 (1998).
61. Slansky JE, Rattis FM, Boyd LF et al. Enhanced antigen-specifc antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13(4), 529-538 (2000).
62. Van Stipdonk MJ, Badia-Martinez D, Sluijter M, Offringa R, Van Hall T, Achour A. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res. 69(19), 7784-7792 (2009).
63. Van Der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability J. Immunol. 156(9), 3308-3314 (1996).
64. Ekeruche-Makinde J, Clement M, Cole DK et al. T-cell receptor-optimized peptide skewing of the T-cell repertoire can enhance antigen targeting. J. Biol. Chem. 287(44), 37269-37281 (2012).
65. Speiser DE, Baumgaertner P, Voelter V et al. Unmodifed self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc. Natl Acad. Sci. USA 105(10), 3849-3854 (2008).
66. Filipazzi P, Pilla L, Mariani L et al. Limited induction of tumor cross-re active T cells without a measurable clinical beneft in early melanoma patients vaccinated with human leukocyte antigen class I-modifed peptides. Clin. Cancer Res. 18(23), 6485-6496 (2012).
67. Meng WS, Butterfeld LH, Ribas A et al. Fine specifcity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein. Mol Immunol 37(16), 943-950 (2000).
68. Hong Y, Peng Y, Guo ZS et al. Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. Hepatology 59(4), 1448-1458 (2014).
69. Houghton CS, Engelhorn ME, Liu C et al. Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. Vaccine 25 (29), 5330-5342 (2007).
70. +) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 24(5), 643-656 (2006).
71. He Y, Falo LD Jr. Lentivirus as a potent and mechanistically distinct vector for genetic immunization. Curr. Opin. Mol. Ther. 9(5), 439-446 (2007).
72. +) T cell responses. J. Clin. Invest. 111(11), 1673-1681 (2003).
73. Arce F, Breckpot K, Collins M, Escors D. Targeting lentiviral vectors for cancer immunotherapy. Curr. Cancer Ther. Rev. 7(4), 248-260 (2011).
74. Xiao H, Peng Y, Hong Y et al. Lentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma. J. Immunol. 187(4), 1788-1796 (2011).
75. Hong Y, Peng Y, Mi M et al. Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice. Vaccine 29(22), 3909-3916 (2011).
76. Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annu. Rev. Immunol. 21, 139-176 (2003).
77. Callahan MK, Wolchok JD. At the bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy J. Leukoc. Biol. 94(1), 41-53 (2013).
78. Zhou Q, Xiao H, Liu Y et al. Blockade of programmed death-1 pathway rescues the effector function of tumor-infltrating T cells and enhances the antitumor effcacy of lentivector immunization. J. Immunol. 185(9), 5082-5092 (2010).
79. Ulcickas Yood M, Quesenberry CP Jr, Guo D et al. Incidence of hepatocellular carcinoma among individuals with hepatitis B virus infection identifed using an automated data algorithm. J. Viral. Hep at. 15(1), 28-36 (2008).
80. Yu MW, Chang HC, Liaw YF et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J. Natl Cancer Inst. 92(14), 1159-1164 (2000).
81. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol. 29(11), 550-557 (2011).
82. Grupp SA, Kalos M, Barrett D et al. Chimeric antigen receptor-modifed T cells for acute lymphoid leukemia. N. Engl. J. Med. 368(16), 1509-1518 (2013).
83. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modifed T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8), 725-733 (2011).